SecBot SecBot
Biotech Drug Report Generated Nov 9, 2026

Optune Mya

NVCR·NovoCure Ltd
BEARISH
Drug Impact Rating3/10
Trial phase
Filed/PMA (Not Approvable Letter received)
Time to market
Uncertain; the FDA rejected the current PMA application. NovoCure plans to meet with the FDA to discuss options that may not require additional clinical studies, but no timeline for a resubmission or potential approval has been established.
Why 3/10
Optune Mya's next hard catalyst is uncertain: the company plans to meet with the FDA after receiving a Not Approvable Letter today, but no date for that meeting or a resubmission has been set. The binary PMA decision has already passed with a negative outcome, so no near-term dated binary exists for this specific drug.
Actionable Insight BEARISH

The FDA's Not Approvable Letter for Optune Mya removes a key pipeline catalyst. Watch for NovoCure's planned meeting with the FDA to see if a path forward emerges without additional clinical studies. Separately, the Dec 31, 2026 PDUFA for Optune Pax (a different device) in the same brain metastases indication remains a major upcoming binary for NVCR.

Price Chart

Loading chart...

Executive Summary

Optune Mya is NovoCure's portable Tumor Treating Fields (TTFields) device being developed for brain metastases from non-small cell lung cancer. On November 9, 2026, the FDA issued a Not Approvable Letter for its Premarket Approval application, citing uncertainty around clinical benefit while raising no safety concerns. NovoCure plans to meet with the FDA to explore a path forward, but there is no assurance of eventual approval. The rejection removes a key pipeline catalyst for NVCR, though the company has other approved TTFields devices generating growing revenue and a separate Dec 31, 2026 PDUFA for Optune Pax in the same indication.

How It Works

Optune Mya is a portable, wearable device that delivers Tumor Treating Fields (TTFields), alternating electric fields applied non-invasively through arrays placed on the skin. These fields disrupt the electrical properties of cancer cells, interfering with their division and survival processes, leading to cell death while largely sparing healthy cells. It is a physical, non-pharmaceutical cancer therapy.

Trial Status

NovoCure submitted a Premarket Approval (PMA) application to the FDA for Optune Mya to treat brain metastases from non-small cell lung cancer following stereotactic radiation. On November 9, 2026, the FDA issued a Not Approvable Letter, determining that the clinical benefit data was insufficient for approval. The company plans to request a meeting with the FDA to discuss next steps.

The Two-Sided Case

▲ Bull Case4
The FDA raised no safety concerns about Optune Mya, only questions about the degree of clinical benefit, which may leave a path to approval through additional analysis or a modified submission.
NovoCure plans to meet with the FDA to explore options that would not require additional clinical studies, potentially preserving a faster timeline.
The company has a growing commercial portfolio of approved TTFields devices (Optune Gio for glioblastoma, Optune Lua for mesothelioma, Optune Pax for pancreatic cancer) generating record revenue of $193M in Q3 2026, up 16% YoY.
Analyst consensus remains positive with 9 Buy/Strong Buy ratings, a mean price target of $25.71 (93.6% implied upside from the $13.28 close), and the Dec 31, 2026 PDUFA for Optune Pax in the same indication is still pending.
▼ Bear Case4
The FDA issued a Not Approvable Letter for Optune Mya, citing uncertainty around clinical benefit, meaning the device failed to convince regulators of its efficacy for brain metastases from NSCLC.
There is no guarantee that discussions with the FDA or any future submission will lead to approval, and additional clinical studies may be required, adding time and cost.
The rejection comes after another NovoCure late-stage trial failure in June 2026, where early use of its TTFields therapy did not significantly improve overall survival in newly diagnosed glioblastoma.
Optune Pax adoption has been slower than expected, with active U.S. patients declining to 266 in Q3 2026 from 285 in Q2, partly due to competition from new targeted therapies.

Upcoming Catalysts

  • FDA meeting to discuss path forward for Optune Mya (no date set)
  • PDUFA date of December 31, 2026 for Optune Pax (a different device) for brain metastases from non-small cell lung cancer

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NovoCure Ltd 8-K NVCR ·Originating report

Sources · 6

Hover a chip for the title
1 marketscreener.com2 rttnews.com3 sec.gov4 fiercebiotech.com5 marketscreener.com6 markets.financialcontent.com